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Abstract A recent development in
biomedical imaging is the non-inva-
sive mapping of molecular events in
intact tissues using fluorescence. 
Underpinning to this development is
the discovery of bio-compatible, spe-
cific fluorescent probes and proteins
and the development of highly sensi-
tive imaging technologies for in vivo
fluorescent detection. Of particular
interest are fluorochromes that emit
in the near infrared (NIR), a spectral
window, whereas hemoglobin and
water absorb minimally so as to al-
low photons to penetrate for several
centimetres in tissue. In this review
article we concentrate on optical 
imaging technologies used for non-
invasive imaging of the distribution
of such probes. We illuminate the
advantages and limitations of simple
photographic methods and turn our
attention to fluorescence-mediated
molecular tomography (FMT), a
technique that can three-dimension-
ally image gene expression by re-
solving fluorescence activation in
deep tissues. We describe theoretical
specifics, and we provide insight in-
to its in vivo capacity and the sensi-
tivity achieved. Finally, we discuss
its clinical feasibility.
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Fluorescence imaging with near-infrared light:
new technological advances that enable 
in vivo molecular imaging
Introduction
Tissue observation with light is probably the most com-
mon imaging practice in medicine and biomedical re-
search ranging from the simple visual inspection of a pa-
tient to advanced in vivo and in vitro spectroscopic and
microscopy techniques [1]. While intrinsic tissue absorp-
tion and scattering yields significant information on
functional and anatomical tissue characteristics, signifi-
cant attention has also been given to fluorescence inves-
tigations of tissue since many biochemical markers can
be retrieved due to fluorescence contrast, and many more
can be targeted using appropriate fluorescent markers 
[2, 3].
Numerous different optical imaging approaches can
be used for imaging fluorescence in vivo. Traditionally,
optical methods have been used to look at surface and
subsurface fluorescent events using confocal imaging 
[4, 5, 6], multiphoton imaging [7, 8, 9, 10] microscopic
imaging by intravital microscopy [11, 12] or total inter-
nal reflection fluorescence microscopy [13]. Recently
however, light has been used for in vivo interrogations
deeper into tissue using photographic systems with con-
tinuous light [14, 15, 16, 17] or with intensity-modulated
light [18] and tomographic systems [19, 20]. Potentially,
phased-array detection [21] can also be applied. This re-
cent focus in macroscopic observations of fluorescence
in tissues has evolved due to the potential of transferring
this technology to imaging through animals and humans
[2]. This technology has become feasible mainly due to
the development of fluorescence probes emitting in the
near-infrared spectrum where tissue offers low absorp-
tion, highly sensitive detectors and monochomatic light
sources (lasers) with higher but nevertheless safely de-
livered power per wavelength compared with white-light
illuminators. While macroscopic fluorescence imaging in
the visible has also been attempted using fluorescent
proteins, the penetration depth is limited to only 1–2 mm
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[16], whereas it has been predicted that NIR fluorescent
light can penetrate for several centimeters [22]. Such an
approach could enable investigations available currently
only for in vitro studies to propagate in in vivo human
disease diagnosis and imaging of treatment response and
significantly enhance the field of molecular imaging [2].
In this article we discuss imaging techniques that use
the diffuse component of light for probing molecular
events deep in tissue. Specifically, we focus on reflec-
tance fluorescence imaging and fluorescence-mediated
molecular tomography (FMT), which are the two most
common approaches currently used for imaging fluores-
cent probes in deep tissues. We further discuss recent
findings that predict the capacity of near-infrared fluo-
rescent signals to propagate through human tissue for
non-invasive medical imaging and address feasibility is-
sues for clinical studies.
Reflectance imaging
Technology
Simple “photographic methods”, in which the light
source and the detector reside on the same side of the an-
imal imaged, are generally referred to as “reflectance im-
aging”. Reflectance imaging is currently the typical
method of choice for accessing the distribution of fluo-
rescent probes in vivo, but the method can be applied
more generally to imaging fluorescent proteins or even
bioluminescence even if in the latter case no excitation
light is used [23].
Near-infrared fluorescence reflectance imaging in
particular operates on light with a defined bandwidth as
a source of photons that encounters a fluorescent mole-
cule (“optical contrast agent or molecular probe”), which
emits a signal with different spectral characteristics, that
can be resolved with an emission filter and captured by a
high-sensitivity CCD camera.
A typical reflectance imaging system is shown in
Fig. 1. The light source can be either a laser at an appro-
priate wavelength for the fluorochrome targeted or white
light sources using appropriate low-pass filters. General-
ly, laser sources are preferable because they offer higher
power delivery at narrower and better-defined spectral
windows (typically ±3 nm for laser diodes vs ±10 nm or
more for filtered white-light sources). The laser beam is
expanded on the animal surface with an optical system
of lenses (not shown). Narrow wavelength selection is
important, especially in the NIR, whereas the excitation
and emission spectra overlap and it is likely that excita-
tion photons can propagate into the fluorescent images.
The CCD camera is usually a high-sensitivity camera
since fluorescent signals are of low strength. On the oth-
er hand, since the targeted measurement is a diffuse-light
measurement, emanating from a virtually flat surface,
CCD chip resolution and dynamic range are not crucial
factors in these types of systems. Also the noise require-
ments of a CCD camera for fluorescence imaging are not
as stringent since in the general case the detection sensi-
tivity limit is set by the background tissue fluorescence
(background probe distribution and auto-fluorescence),
and fluorescence strength can be adjusted above the
camera noise floor by optimizing illumination strength
and acquisition times. These features are in contrast to
bioluminescence measurements, where the detection sen-
sitivity is usually set by the CCD camera noise floor. De-
tection systems that scan a single spot over a field of
view and detect light using photo-multiplier tube detec-
tors have also been reported [24]. Such systems may of-
fer greater dynamic range than CCD-based systems but
compromise resolution, acquisition frame rate, and over-
all noise characteristics, and are not widely used in in vi-
vo fluorescence reflectance measurements.
Typically, the fluorescence image acquired (see exam-
ple in Fig. 2a) is accompanied by a second image, shown
in Fig. 2b, which is measured without the fluorescence
filter to obtain a “photograph” of the animal for registra-
tion purposes at the excitation wavelength. This intrinsic
light image also serves as a calibration measurement
since it records the exact spatial distribution of the exci-
tation light strength for later correction of excitation
field inhomogeneities. Figure 2 depicts a measurement
from a nude mouse with a cathepsin B rich HT1080 fi-
brosarcoma, which had been implanted (105 cells) into
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Fig. 1 Typical fluorescence reflectance imaging (FRI) system for
in-vivo animal investigations. The illumination source and CCD
camera are on the same side of the animal imaged. The compo-
nents shown are usually enclosed into a light-tight box
the posterior upper thorax of the mouse 7–10 days prior
to the experiment, at ~3 mm depth using a cathepsin B
sensitive imaging probe [25]. It is noteworthy that the in-
trinsic light image records the structure on the animal
surface and can yield high-resolution images after appro-
priate focusing, whereas the fluorescence (or lumines-
cence) image records fluorescence signals emanating
from under the surface and is by nature a low-resolution
image that uses mainly the diffuse component of light.
The side-by-side comparison or the superposition of the
two images (c.f. Fig. 2c) into a single image yields a
good visual effect since high resolution is retained.
Applications
Reflectance imaging has been used to image cathespin B
[25], cathepsin D [26] and matrix metalloproteinase 2
(MMP-2) [27] using activatable probes, i.e., appropriate-
ly engineered fluorochromes that are dark in their native
(quenched) state and fluoresce only upon interaction
with specific proteases. A representative mechanism of
activation is shown in Fig. 3. In the non-activated state
fluorochromes are loaded in closed proximity onto a
graft copolymer consisting of a poly-lysine (PL) back-
bone through appropriate peptides and undergo mutual
energy transfer; thus, they exist in a quenched state. 
At the presence of the targeted enzyme, cleavage of the
peptide link releases the fluorochromes which results 
in a bright fluorescence signal, which can be detected 
in vivo.
A characteristic example of this technology applied to
elucidate different expression levels of tumor MMP-2
activity is shown in Fig. 4 using an MMP-2-positive hu-
man HT1080 fibrosarcoma and an MMP-2-negative
BT20 mammary adenocarcinoma [28]. Both types of
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Fig. 2a–c Example of typical images involved in FRI. a Fluores-
cence image obtained from the animal. In this example the image
is obtained using a cathepsin-B sensitive fluorescent probe inject-
ed in an animal implanted with a HT1080 carcinoma in the upper
posterior thorax. b Intrinsic light image obtained without the fluo-
rescent band-pass filter. Such images are useful to outline with
greater detail the animal investigated. c Superposition of a onto b
improves the visual result
Fig. 3 An example of an activatable probe. These probes are dark
in their native state, but after enzymatic cleavage of the backbone
carrier they fluoresce when appropriately excited
breast cancers activated the near-infrared probe, but the
activation at the HT1080 tumor was markedly higher
than the BT-20 tumor which was barely differentiable
from the background activation. The different levels of
enzyme secretion in the two tumor cell lines used were
further verified by zymographic studies [28] as shown in
Fig. 4c.
Reflectance imaging has also been used for targeting
cell-surface receptors in vivo using peptide near-infrared
dye conjugates [15, 29]. Figure 5 depicts fluorescence
reflectance images using a conjugate of tricarbocyanine
dye and an octapeptide (c.f. Fig. 5a) for targeting the so-
matostatin receptor in CA20948 tumor-bearing rats [29,
30]. The tumor cells were implanted subcutaneously in
the left flank of the rat demonstrating a marked fluores-
cence increase compared with surrounding tissues
(Fig. 5b, c). Similar observations were performed in a
separate study [15] that showed significant fluorescence
increase from tumor sites compared with normal tissues
using the somatostatin analog octreotate coupled to in-
docarbocyanine dyes. Specifically, the fluorescence de-
tected before the injection of the dye-peptide conjugate
administered in a tumor-bearing mouse (RIN38 pancre-
atic tumor expressing the somatostatin receptor subtype
2) and a control mouse are shown in Fig. 6a and b, re-
spectively. Figure 6c and d show the fluorescence imag-
es obtained from the same animals 6 h after probe injec-
tion. The administered probe dose was 0.02 µmol/kg
body weight. The receptor-binding indotricarbocyanine-
octreotate conjugate leads to a significantly elevated tu-
mor signal (Fig. 6c), whereas a control conjugate with no
receptor affinity does not generate contrast (Fig. 6d). The
relative fluorescence intensities of tumor tissue and nor-
mal tissue in the tumors studied with two different dye
conjugates are shown in Fig. 6e and f (indodicarbocya-
nine-octreotate, Fig. 6e; and indotricarbocyanine-octreo-
tate, Fig. 6f) at different times after application. The time
course of tumor-to-normal contrast is depicted for both
compounds in Fig. 6g. Figure 6h shows the results of a
biodistribution analysis of 125I-ITCC-octreotate in
RIN38 tumor-bearing nude mice 24 h post injection. Tis-
sue distribution of this double-labeled peptide derivative
is given as percentage injected dose per gram. 
More generally, reflectance imaging can be used to
macroscopically assess endogenous gene products by us-
ing fluorescent proteins [16, 31]. Imaging of florescent
proteins (FP) can be done in analogy to near-infrared im-
aging with the following exceptions:
1. Absorption/excitation are shifted in, usually to the
visible light range
2. The higher endogenous tissue absorption in the visi-
ble wavelength yields significantly smaller penetra-
tion depths
3. No exogenous fluorochromes have to be administered
to visualize FP expression
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Fig. 4a–c Near-infrared imaging of a nude mouse implanted with
both an MMP-2-positive human HT1080 fibrosarcoma and an
MMP-2-negative BT20 mammary adenocarcinoma. a Both tumors
measured approximately 2–3 mm. b Raw near-infrared image
shows that the fibrosarcoma generated strong fluorescent signal
intensity 2 h after intravenous injection of an MMP-2-sensitive
activatable probe, but the signal intensity of the BT20 tumor was
only slightly higher compared with the background fluorescence
of the skin. c Zymographic measurements revealed a significant
difference between MMP-2 secretions by the two tumor lines.
(Adapted from [28])
In a similar paradigm, bioluminescence imaging [32] is
based on emission of visible photons at specific wave-
lengths based on energy-dependent reactions catalyzed
by luciferases. Luciferase genes have been cloned from a
large number of organisms, including bacteria, firefly
(Photinus pyralis), coral (Renilla), jellyfish (Aequorea),
and dinoflagellates (Gonyaulax). In the firefly, luciferase
utilizes energy from ATP to convert its substrate lucife-
rin to oxyluciferin, with the emission of a detectable
photon. Sensitive imaging systems have been built to de-
tect quantitatively a small number of cells or organisms
expressing luciferase as a transgene [33].
Multi-spectral imaging
An exciting approach in optical imaging is capitalizing
on the spectral differentiation of different fluorochromes
in order to perform concurrent imaging of multiple tar-
gets [34]. This can be achieved by using appropriate 
filters in front of the CCD detector that can selectively
acquire images at different wavelengths. Figure 7 exem-
plifies this approach by showing images of GFP and 
cathepsin B expression obtained from a nude mouse 
implanted subcutaneously with GFP positive 9L glioma
tumors on the right side and GFP negative 9L glioma tu-
mors on the left side [34]. Both tumors were expressing
cathepsin B, which was imaged with a cathepsin-B sen-
sitive probe [25] loaded with the Cy5.5 fluorochrome
(Amersham Pharmacia Biotech, Piscataway, N.J.). The
images were acquired consecutively using appropriate
filters in front of the detector for imaging at the GFP
spectral window (500–550 nm) and at the Cy5.5 dye
channel (690–740 nm) and demonstrate the ability to im-
age separate gene expressions in vivo
Advantages and limitations
Reflectance imaging is an ideal tool for high-throughput
imaging and screening of surface fluorescent events in
vivo or in excised tissues. It offers simplicity of opera-
tion and high sensitivity for molecular events that are
close to the surface. Typical acquisition times range from
a few seconds to a few minutes. For laboratory settings,
multiple animals can be simultaneously imaged. Hard-
ware development and implementation is also straight-
forward and relatively inexpensive. Reflectance systems
do not use ionizing radiation, employ safe laser powers,
can be made portable and attain small space require-
ments to be ideal for the laboratory bench.
On the other hand, reflectance imaging has funda-
mental limitations both as a research or clinical tool.
Firstly, the technique attains only small penetration
depths (a few millimeters). This is because the appear-
ance of deeper lesions is significantly blurred and the
signal detected from them is significantly attenuated as a
function of lesion depth while the background noise re-
mains constant in reflectance mode since it consists of
fluorescence signals from superficial layers and intrinsic
light contaminating the fluorescence measurement due to
imperfect filtering. This is in contrast to tomographic
methods (discussed in the next section) where both sig-
nal and noise reduces so that signal to noise remains sig-
nificant for lesions that are much deeper than a few mil-
limeters. Secondly, reflectance imaging is not capable of
quantification as illustrated in Fig. 8. A small structure
of high fluorochrome concentration that is deeper into
tissue could yield the same appearance on the surface as
a larger structure of low fluorochrome concentration that
is closer to the surface. This is due to the nature of prop-
agation of diffuse photon density waves into tissue. The
photon count reading at a surface of an animal due to a
lesion on or under the surface depends on the lesion
depth, the lesion volume and the optical properties of
both the lesion and the surrounding tissue; therefore, im-
ages from different animals, or from the same animal at
different time points, are generally insufficient for yield-
ing quantitative insights.
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Fig. 5 a Molecular structure of cytate, a conjugate of tricarbocya-
nine dye for near-infrared imaging and an octapeptide for targeting
somatostatin receptor which is up-regulated in neuroendocrine tu-
mors. b Fluorescence intensity imaging of a CA20948 tumor-bear-
ing rat 27 h post administration of cytate via the tail vein. Tumor
cells were implanted subcutaneously in the left flank of the rat. 
c Fluorescence-intensity image of selected organ parts excised
24 h post injection of cytate. The somatostatin receptor-positive
tumor, CA20948, preferentially retains cytate. (Adapted from [29]
and [30])
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Fig. 6 In vivo fluorescence 
images of tumor-bearing mice
(RIN38 pancreatic tumor ex-
pressing the somatostatin re-
ceptor subtype 2) a, b before
and c, d 6 h after injection of
dye-peptide conjugate at a dose
of 0.02 µmol/kg body weight. 
c The receptor-binding 
indotricarbocyanine–octreotate
conjugate leads to a significant-
ly elevated tumor signal,
whereas d a control conjugate
with no receptor affinity does
not generate contrast. Relative
fluorescence intensities of tu-
mor tissue and normal tissue 
in RIN38/SSTR2 tumors from
nude mice after intravenous 
injection e of ITCC-octreotate
or f ITCC-(M2M7) octreotate
at different times after applica-
tion. g The time course of 
tumor-to-normal contrast is 
depicted for both compounds. 
h The results of a biodistribu-
tion analysis of 125I-ITCC-
octreotate in RIN38/SSTR2 
tumor-bearing nude mice 24 h
post injection. Tissue distribu-
tion of this double-labeled pep-
tide derivative is given as per-
centage injected dose per gram.
(Image courtesy of K. Licha is
taken from [15])
Fluorescence-mediated molecular tomography
In order to resolve and quantify fluorochromes deep in
tissue tomographic approaches are necessary. The gener-
al framework of reconstruction techniques using diffuse
light has been developed during the last decade where
rigorous mathematical modeling of light propagation in
tissue, combined with technological advancements in
photon sources and detection techniques has made possi-
ble the application of tomographic principles [35, 36, 37,
38, 39, 40] for optical imaging. The technique, generally
termed diffuse optical tomography (DOT), uses multiple
projections and measures light around the boundary of
the illuminated body. It then effectively combines all
measurements into an inversion scheme that takes into
account the highly scattered photon propagation to de-
convolve the effect of tissue on the propagating wave,
even though high frequency components are generally
significantly attenuated and the resolution impaired. Dif-
fuse optical tomography has been used for quantitative
imaging of absorption and scattering [41, 42, 43, 44, 45,
46] as well as concentration and fluorochrome lifetime
measurements with simulated or phantom measurements
[47, 48, 49, 50, 51, 52]. Recently, DOT has been applied
clinically for imaging tissue oxy- and deoxy-hemoglobin
concentration and blood saturation [53, 54, 55] and con-
trast agent uptake in absorption mode [56].
A particular development that facilitates in vivo mo-
lecular interrogations of tissue is the use of fluorescence
molecular tomography (FMT) [20]. The method produc-
es quantified three-dimensional reconstructions of fluo-
rescence activation or concentration using measurements
of fluorescent molecular probes at both the emission and
excitation wavelengths. The theoretical mainframe has
been described elsewhere [52]. The main advantage of
using both intrinsic and fluorescence contrast is that no
absolute photon-field measurements are required, yet ab-
solute fluorochrome concentrations can be reconstructed.
Furthermore, the method does not require any measure-
ments obtained before contrast agent administration,
which is a crucial parameter for in vivo imaging of
probes that require long circulation times to achieve suf-
ficient accumulation in their intended targets.
FMT imaging systems
In order to perform fluorescence tomography, tissue has
to be illuminated at different projections and multiple
measurements should be collected from the boundary of
the tissue of investigation. FMT, in its simplest imple-
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Fig. 7 Dual-channel imaging
of genetically identically 9L
glioma tumors except for GFP
expression (positive on ani-
mal’s right flank, negative on
animal’s left flank). Both tu-
mors are expressing cathepsin
B. From left to right: white-
light image, GFP image, and
cathepsin B obtained virtually
simultaneously using spectrally
separated fluorescence reflec-
tance images. (Image courtesy
of U. Mahmood adapted from
[34])
Fig. 8 Different strength and size fluorescent lesions embedded in
a diffuse medium at different lengths can have the same appear-
ance on the surface impeding quantification using reflectance im-
aging
mentation, needs only measurements of fluorescence and
intrinsic light using constant-wave sources in order to re-
solve the single quantity targeted, namely fluorochrome
concentration. This is in contrast to DOT which, in its
general form, requires decomposition of absorption from
scattering and therefore requires more elaborate photon
technologies such as intensity-modulated sources or
short photon pulses and appropriate detection systems.
The ability of FMT to operate with constant wave sys-
tems allows for a practical and relatively inexpensive
implementation of multiple detection channels using
CCD cameras. In CW mode, CCD cameras offer very
high sensitivity and low noise levels. Nevertheless, the
use of advanced photon sources and detection systems
can enhance tomographic performance by potentially im-
proving resolution and resolving lifetime as well [48,
49].
A CCD-based FMT system example is shown in
Fig. 9a. The light source (i) is generally a laser diode at
the appropriate wavelength to excite the targeted fluoro-
chrome. Multiple laser diodes at different wavelengths
could be combined in the same system (either by time
sharing or spectral separation) to excite multiple fluoro-
chromes simultaneously. The light from the laser diode
can be directed to an optical switch (ii) for time sharing
one input to many outputs and directed with optical fi-
bers (iii) at different points around the body of investiga-
tion or a specially designed “optical bore” (iv). Our im-
plementation of an optical bore [57] is shown in Fig. 9b.
The optical bore contains the body of examination simi-
lar to a CT or MR scanner. Typically, such an implemen-
tation would require the animal immersed into a “match-
ing fluid” (also shown in Fig. 9b contained in the bore),
such as a water solution of a scatterer (e.g., TiO2 parti-
cles) and an absorber (India Ink or similar) that matches
the optical properties of the tissue investigated. The
matching fluid serves virtually the same function as gel
to ultrasound. Fiber bundles (v) can be used to collect
photons through the turbid medium and direct them onto
the CCD camera (viii) either by direct fiber coupling or
by an appropriate positioning arrangement (vi) so that
the fiber output can be imaged via a lens system as de-
picted in Fig. 9c. Appropriate filters (vii) are necessary
to reject background ambient light and intrinsic or fluo-
rescence signals according to the measurement per-
formed. A reference measurement could also be intro-
duced to account for temporal variations in laser intensi-
ty. The use of an optical bore and matching fluid is a
convenient approach for matching photons onto tissue
but by no means limiting. Different schemes, including
direct fiber positioning on the tissue surface, at arbitrary
geometries, including geometries, that could be used by
endoscopic probes could be devised.
In vivo imaging
The FMT has been used recently for imaging of cathep-
sin B activity within deep structures. Figure 10 shows a
representative experiment of the results obtained from
9L gliosarcomas stereotactically implanted into unilater-
al brain hemispheres of nude mice, as cathespin B activi-
ty had been implicated in glioma invasion [58, 59, 60].
Correlative MR imaging was performed to determine the
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Fig. 9a–c Example of an FMT
scanner. a The scanner uses
multiple sources and detectors
to effectively collect light mea-
surement at multiple projec-
tions around the animal’s body.
For details see text. b Photo-
graph of the optical bore used
for animal investigations. 
The source fibers (blue) and
detection fiber bundles (black)
are shown installed. c Photo-
graph of the fiber bundle array
arranged for imaging by the
CCD camera
presence and location of tumors prior to the FMT imag-
ing studies. Figure 10a and b depicts the gadolinium-
enhanced tumor (enhancement is shown in a green color
map superimposed onto a T1-weighted image) on axial
(Fig. 10a) and sagittal (Fig. 10b) slices. Figure 10c, e,
and f depicts the three consecutive FMT slices obtained
from top to bottom of the volume of interest. The loca-
tion and volume covered by the three slices is indicated
in Fig. 10b by thin white horizontal lines. Figure 10c
shows marked local probe activation relative to adjacent
slices, congruent with the location of the tumor identi-
fied on the MR images. Figure 10d shows a superposi-
tion of the MR axial slice passing through the tumor
(Fig. 10a) onto the corresponding FMT slice (Fig. 10c)
after appropriately translating the MR image to the actu-
al dimensions of the FMT image. For coregistration pur-
poses we used special water-containing fiducials and
body marks that facilitated matching of the MR and
FMT orientation and animal positioning. The in vivo im-
aging data correlated well with surface-weighted reflec-
tance imaging of the excised brain. Figure 10g depicts
the axial brain section through the 9L tumor examined
with white light using a CCD camera mounted onto a
dissecting microscope, Fig. 10h shows the same brain
section imaged using a previously developed reflectance
imaging system [14] at the excitation wavelength
(675 nm), and Fig. 10i is the fluorescence image ob-
tained at the emission light wavelength using appropriate
three-cavity cut-off filters that demonstrates a marked
fluorescent probe activation, congruent with the tumor
position identified by gadolinium-enhanced MRI and
FMT. The above results confirm that cathepsin B can be
used as an imaging marker [25] since the protease is pro-
duced in considerable amounts by tumor cells and by re-
cruited host cells [61]. Cathepsin B expression in the tu-
mors was further confirmed by immunohistochemistry,
Western blotting and RT-PCR.
Quantification: resolution and coregistration
The feasibility to three-dimensionally reconstruct and
quantify fluorochromes embedded in diffuse media has
been demonstrated in the past [47, 48, 49, 52]. It has
been further shown that FMT can yield linear responses
over a wide area of physiologically relevant fluoro-
chrome concentrations [57]. Figure 11 depicts recon-
structions obtained for the range 1–800 nM concentra-
tion of the Cy5.5 fluorochrome obtained with a system
similar to the one shown in Fig. 9. The geometry em-
ployed is shown in Fig. 11a. A 2-mm radius tube was
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Fig. 10a–i In-vivo FMT of cathepsin B expression levels in 9L
gliosarcomas stereotactically implanted into unilateral brain hemi-
spheres of nude mice. a, b Axial and sagittal MR slices of an ani-
mal implanted with a tumor, which is shown in green after gado-
linium enhancement. c, e, f, Consecutive FMT slices obtained
from top to bottom from the volume of interest shown in b by thin
white horizontal lines. d Superposition of the MR axial slice pass-
ing through the tumor a onto the corresponding FMT slice c after
appropriately translating the MR image to the actual dimensions
of the FMT image. g, h Axial brain section through the 9L tumor
imaged with white light and with monochromatic light at the exci-
tation wavelength (675 nm), respectively, and i fluorescence im-
age of the same axial brain section demonstrating a marked fluo-
rescent probe activation, congruent with the tumor position identi-
fied by gadolinium-enhanced MRI and FMT. (Reproduced from
[20])
immersed into the optical bore (shown in Fig. 9) and
contained various concentrations of fluorochromes. A
typical reconstructed image is seen in Fig. 11b. Fig-
ure 11c plots the reconstructed fluorochrome concentra-
tion as a function of the expected concentration. The 
reconstructed value demonstrates a remarkably linear re-
sponse for the whole range of examined concentrations
[57].
The resolution limits of diffuse light imaging tech-
niques have been studied theoretically, but there is limit-
ed experimental demonstration, mainly due to the lack of
high source-detection efficiency systems. Increasing the
number of sources and detectors improves resolution not
only due to the higher spatial sampling but also due to
the improvements in signal-to-noise ratio achieved in in-
creased data sets [62]. Naturally, improvements of
source and detector density do not scale linearly with
resolution improvements. It is expected that the resolu-
tion for small animal imaging would be of the order of
1–2 mm, whereas for larger tissues it would approach
4–5 mm [62].
The FMT can be combined with high-resolution “re-
flectance” imaging in superimposing surface architec-
tural features and markers on the underlying three-
dimensional reconstruction to correlate the tomographic
results with anatomical features, especially in animal
imaging. Such an example is shown in Fig. 12. 
Figure 12a depicts a merged axial FMT/MRI image ob-
tained from the nude mouse shown in Fig. 2. Figure 12b
depicts the sagittal MRI image of the same animal and
the three FMT slices imaged. Figure 12c depicts a
three-dimensional rendering of the superposition of the
three-dimensional FMT images with the two dimen-
sional intrinsic light image (shown in Fig. 2b) after ap-
plication of appropriate thresholds. Furthermore, the
combination of FMT with high-resolution imaging
methods that primarily target structure, such as X-ray
CT or MRI, could yield a superior hybrid imaging mo-
dality in which highly sensitive molecular information
and high resolution is achieved. Such an approach is
feasible due to the optical component compatibility
with most other medical imaging modalities and has
been recently applied to performing clinical investiga-
tions of the breast using a combined MRI and DOT
system [19].
Clinical feasibility of fluorescence imaging
Clinical fluorescent imaging would require detection of
fluorescent signals that have propagated for several cen-
timeters into tissue. Figure 13a demonstrates the photon
attenuation rate of different human tissues. In particular,
it is shown that breast tissue and the adult lung attenu-
ates NIR light one order of magnitude every 2.5 cm, the
attenuation rate in denser breast approaches one order
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Fig. 11a–c Reconstruction linearity for varying fluorochrome
concentrations. a Experimental phantom used for the demonstra-
tion. The small circle represents a tube of 100 µl volume contain-
ing different concentrations of Cy5.5 dye. b Typical image recon-
structed. c Reconstructed vs real fluorochrome concentration. The
linearity achieved spans more than two orders of magnitude of bi-
ologically relevant fluorochrome concentrations. (Adapted from
[57])
of magnitude every 1.5 cm and the attenuation rate in
brain and muscle is approximately one order of magni-
tude every 1.0 cm. In signal strength terms Fig. 13 plots
fluorescence counts per second of exposure and square
millimeter of of CCD detector area, as a function of or-
gan diameter. This calculation is for a tumor-like lesion
of 100 µl volume and 100 nM of Cy5.5 concentration
(10 pico-moles) located near the center of the various
organs simulated. The simulation is based on experi-
mental measurements obtained from a diffuse volume
(similar to the one shown on Fig. 11a but with varying
outer diameter) using 30 mW of illuminating power
[22].
There are also three horizontal lines plotted, marking
the 10-, 20-, and 30-dB signal-to-noise ratio (SNR)
achieved assuming shot-noise limited detection. In reali-
ty, background fluorescence (primarily due to non-spe-
cific dye distribution) limits the SNR achieved, since
background signals can be seen as “biologically induced
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Fig. 12a–c An example of
merging two-dimensional with
three-dimensional information
for improving visualization. 
a The FMT image of the mouse
shown in Fig. 2. b An MRI
sagittal image. The three-plane
FMT images are contained 
between the white horizontal
lines. The arrow indicates 
the position of the tumor. 
c Rendering of the FMT volu-
metric reconstruction superim-
posed with the two-dimension-
al intrinsic light image after 
application of appropriate
thresholds
Fig. 13 Average fluorescent photon counts expected at the periph-
ery of different organs due to a fluorochrome located 0.5 cm off
center as a function of organ diameter. Three signal-to-noise levels
for shot-noise limited detection are also plotted. (From [22])
noise” after appropriate subtraction schemes [63]. Data
set optimization [62] and appropriate algorithms [64] can
be used to image at low SNR and such considerations
should be addressed on a case-to-case basis. This study,
however, demonstrates that fluorescence imaging of hu-
man tissues becomes an issue of uptake-to-background
contrast rather than of propagation feasibility. Important
to the latter argument is that fluorescence offers mecha-
nisms for multifold background suppression by using
quenching and activation (dequenching) of fluorescent
probes [25, 65] or fluorescence resonance energy trans-
fer [66]. These technologies significantly minimize
background signals in vivo and, combined with advances
in drug delivery and hardware improvements, could sur-
pass the predictions of this study.
Conclusion
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ability to detect tumors or other diseases in their earliest
stage of formation, phenotype tumors during complex
cycles of growth, invasion and metastases, to use imag-
ing techniques to speed up drug testing, and to use imag-
ing as an objective endpoint for tailoring therapies in a
given individual. Similar limitations also exist in neuro-
degenerative, cardiovascular, and immunologic diseases.
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